These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 29017591)
41. Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA). Mulder MLM; Vriezekolk JE; den Broeder N; Mahler EAM; Helliwell PS; van den Hoogen FHJ; den Broeder AA; Wenink MH Trials; 2020 Feb; 21(1):155. PubMed ID: 32041657 [TBL] [Abstract][Full Text] [Related]
42. Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis. Mease PJ; Kavanaugh A; Ogdie A; Wells AF; Bergman M; Gladman DD; Richter S; Teng L; Jardon S; Smolen JS J Rheumatol; 2022 Jul; 49(7):694-699. PubMed ID: 35428720 [TBL] [Abstract][Full Text] [Related]
43. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52. Smolen JS; Mease P; Tahir H; Schulze-Koops H; de la Torre I; Li L; Hojnik M; Sapin C; Okada M; Caporali R; Gratacós J; Goupille P; Liu Leage S; Pillai S; Nash P Ann Rheum Dis; 2020 Oct; 79(10):1310-1319. PubMed ID: 32660977 [TBL] [Abstract][Full Text] [Related]
44. Chinese Registry of Psoriatic Arthritis (CREPAR): I. Clinical characteristics of Chinese patients with psoriatic arthritis. Lu C; Yang F; Liu H; Dou L; Wang Y; Li H; Duan X; Wu L; Wang Y; Zhang X; Xu J; Su J; Xu D; Zhao J; Wu Q; Li M; Leng X; Zeng X; Int J Rheum Dis; 2023 Sep; 26(9):1737-1744. PubMed ID: 37424174 [TBL] [Abstract][Full Text] [Related]
45. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs. Perrotta FM; Marchesoni A; Lubrano E J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925 [TBL] [Abstract][Full Text] [Related]
46. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs. Murage MJ; Princic N; Park J; Malatestinic WN; Zhu B; Atiya B; Kern SA; Stenger KB; Sprabery AT; Ogdie A J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751 [No Abstract] [Full Text] [Related]
47. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA. Brahe CH; Ørnbjerg LM; Jacobsson L; Nissen MJ; Kristianslund EK; Mann H; Santos MJ; Reino JG; Nordström D; Rotar Z; Gudbjornsson B; Onen F; Codreanu C; Lindström U; Möller B; Kvien TK; Pavelka K; Barcelos A; Sánchez-Piedra C; Eklund KK; Tomšič M; Love TJ; Can G; Ionescu R; Loft AG; van der Horst-Bruinsma IE; Macfarlane GJ; Iannone F; Hyldstrup LH; Krogh NS; Østergaard M; Hetland ML Rheumatology (Oxford); 2020 Jul; 59(7):1640-1650. PubMed ID: 31665497 [TBL] [Abstract][Full Text] [Related]
48. Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results. Smolen JS; Siebert S; Korotaeva TV; Selmi C; Bergmans P; Gremese E; Joven-Ibáñez B; Katsifis G; Noël W; Nurmohamed MT; Richette P; Sfikakis PP; de Vlam K; Theander E; Gossec L Ann Rheum Dis; 2021 Nov; 80(11):1419-1428. PubMed ID: 34162594 [TBL] [Abstract][Full Text] [Related]
49. Utility of Power Doppler Ultrasound-detected Synovitis for the Prediction of Short-term Flare in Psoriatic Patients with Arthritis in Clinical Remission. Ruta S; Marin J; Acosta Felquer ML; Ferreyra-Garrot L; Rosa J; García-Monaco R; Soriano ER J Rheumatol; 2017 Jul; 44(7):1018-1023. PubMed ID: 28461647 [TBL] [Abstract][Full Text] [Related]
50. Association between clinical specialty setting and disease management in patients with psoriatic arthritis: results from LOOP, a cross-sectional, multi-country, observational study. Boehncke WH; Horváth R; Dalkiliç E; Lima SAL; Okada M; Hojnik M; Ganz F; Lubrano E J Eur Acad Dermatol Venereol; 2020 Sep; 34(9):2035-2043. PubMed ID: 32003056 [TBL] [Abstract][Full Text] [Related]
51. Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices. Lubrano E; Scriffignano S; Azuaga AB; Ramirez J; Cañete JD; Perrotta FM RMD Open; 2020 Mar; 6(1):. PubMed ID: 32179713 [TBL] [Abstract][Full Text] [Related]
52. Relationship between psoriatic arthritis and moderate-severe psoriasis: analysis of a series of 166 psoriatic arthritis patients selected from a hospital population. Busquets-Pérez N; Rodriguez-Moreno J; Gómez-Vaquero C; Nolla-Solé JM Clin Rheumatol; 2012 Jan; 31(1):139-43. PubMed ID: 21701797 [TBL] [Abstract][Full Text] [Related]
53. Health-related quality of life in patients with psoriatic and rheumatoid arthritis: data from the prospective multicentre NOR-DMARD study compared with Norwegian general population controls. Michelsen B; Uhlig T; Sexton J; van der Heijde D; Hammer HB; Kristianslund EK; Wierød A; Bakland G; Rødevand E; Krøll F; Loge JH; Haugeberg G; Kvien TK Ann Rheum Dis; 2018 Sep; 77(9):1290-1294. PubMed ID: 29875096 [TBL] [Abstract][Full Text] [Related]
54. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis. Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018 [TBL] [Abstract][Full Text] [Related]
55. Disease control in patients with psoriatic arthritis in real clinical practice in Spain: MiDAS study. Gratacós J; Pablos JL; de Miguel E; Juanola X; Fernández-Carballido C; Ariza R; Terradas-Montana P; Sastré C; Sanabra C; Reumatol Clin (Engl Ed); 2023 Apr; 19(4):204-210. PubMed ID: 37061282 [TBL] [Abstract][Full Text] [Related]
56. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. Helliwell P; Coates LC; FitzGerald O; Nash P; Soriano ER; Elaine Husni M; Hsu MA; Kanik KS; Hendrikx T; Wu J; Kudlacz E Arthritis Res Ther; 2018 Oct; 20(1):242. PubMed ID: 30373651 [TBL] [Abstract][Full Text] [Related]
57. Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritis. Tillett W; Shaddick G; Jobling A; Askari A; Cooper A; Creamer P; Clunie G; Helliwell PS; James J; Kay L; Korendowych E; Lane S; Packham J; Shaban R; Thomas ML; Williamson L; McHugh N Rheumatology (Oxford); 2017 Apr; 56(4):603-612. PubMed ID: 28013211 [TBL] [Abstract][Full Text] [Related]
58. Prevalence of minimal disease activity in Australian patients with Psoriatic Arthritis: Assessing the outcome of national funding criteria for biologic disease-modifying antirheumatic drug prescribing. Pontifex EK; Dissanayake K; Bursill D; Gill T Int J Rheum Dis; 2019 Feb; 22(2):262-268. PubMed ID: 30450819 [TBL] [Abstract][Full Text] [Related]
59. Clinical management of psoriatic arthritis. Van den Bosch F; Coates L Lancet; 2018 Jun; 391(10136):2285-2294. PubMed ID: 29893227 [TBL] [Abstract][Full Text] [Related]